Home > Media KIt > News Room

Morepen Laboratories Limited
Unaudited Financial Results
For the Quarter  ended 30th September, 2012
                (Rs. in Lacs)
      Quarter ended  Half Year ended  Year ended
  30.09.2012 30.06.2012 30.09.2011 30.09.2012 30.09.2011   31.03.2012
  (Unaudited) (Unaudited)   (Audited)
1(a) Net Sales/Income from Operations (Net of Excise Duty)   6869 7650 5887 14519 11814   26117
(b) Other Operating Income   137 157 244 294 329   833
  Total Income from Operations (Net)    7006 7807 6131 14813 12143   26950
2 Expenditure                
  a)  Cost of Material Consumed   2985 3436 2603 6421 6280   13242
  b)  Purchase of stock - in - trade   1531 1326 1169 2857 1890   5041
  c)  Changes in inventories of  Finished goods, Work -in- progress and Stock-in-trade    (40) 98 51 58 (87)   (507)
  d)  Employee benefits expenses   872 849 807 1721 1577   3265
  e) Depreciation and Amortisation   1153 1135 1216 2288 2357   4689
  f) Power and Fuel   279 275 251 554 482   982
  g) Travelling Expenses   136 133 150 269 299   595
  h) Selling and Distribution Expenses   307 290 206 597 379   1050
  i)  Other Expenses   433 473 391 906 781   1518
  Total Expenditure   7656 8015 6844 15671 13959   29875
3 Profit / (Loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)   (650) (208) (713) (858) (1816)   (2925)
4 Other Income /(Loss) - 1 1 - 2 11   101
5 Profit / (Loss)  from Ordinary activities before Finance Cost and Exceptional Items (3+4)   (649) (207) (713) (856) (1805)   (2824)
6 Finance Cost   346 224 210 570 433   796
7 Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)   (995) (431) (923) (1426) (2237)   (3620)
8 Exceptional Items - Income/(Expense)   - - - - -   -
9 Profit / (Loss) from Ordinary Activities before Tax (7-8)   (995) (431) (923) (1426) (2237)   (3620)
10 Tax Expense    - - - - -   -
11 Profit / (Loss) from Ordinary Activities after Tax (9-10)   (995) (431) (923) (1426) (2237)   (3620)
12 Extraordinary Items-Income/(Expense)   334 - - 334 -   1204
13 Net Profit /(Loss) for the period  (11+12)   (661) (431) (923) (1092) (2237)   (2416)
14 Paid-up Equity Share Capital of Face Value of Rs.2/- each   8996 8996 8996 8996 8996   8996
15 Reserves excluding Revaluation reserves   - - - - -   14349
16 a) Earning Per Share before Extraordinary Items (in Rs.) -                                
  Basic & Diluted   (0.22) (0.10) (0.21) (0.32) (0.50)   (0.82)
  b) Earning Per Share after Extraordinary Items (in Rs.) -                                                   
  Basic & Diluted   (0.15) (0.10) (0.21) (0.15) (0.50)   (0.55)
A PARTICULARS OF SHAREHOLDING                
1 Public Shareholding                
  - Number of Shares   294454615 294454615 294454615 294454615 294454615   294454615
  - Percentage of shareholding   65.46 65.46 65.46 65.46 65.46 65.46 65.46
2 Promoters and Promoter Group Shareholding                
  a) Pledged / Encumbered                
  - Number of Shares   610000 610000 610000 610000 610000   610000
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)   0.39 0.39 0.39 0.39 0.39   0.39
  - Percentage of shares (as a % of the total share capital of the company)   0.14 0.14 0.14 0.14 0.14   0.14
  b) Non-encumbered                
   - Number of Shares   154761588 154761588 154761588 154761588 154761588   154761588
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)   99.61 99.61 99.61 99.61 99.61   99.61
  - Percentage of shares (as a % of the total share capital of the company)   34.40 34.40 34.40 34.40 34.40   34.40
B INVESTOR COMPLAINTS   For the Quarter ended 30th September, 2012
  Pending at the beginning of the quarter   -
  Received during the quarter   2
  Disposed off during the quarter   2
  Remaining unresolved during the quarter   -
Notes:                  
1. The above results were reviewed by the audit committee and have been approved by the Board of Directors in the meeting held on 5th November, 2012. A limited review of the same had been carried out by the statutory auditors and their report contains no qualification.
2. The Company is exclusively engaged in the Pharmaceutical Business segment.
3. Consolidated Income from Operatitons, Profit/(Loss) after tax and EPS before & after extraordinary Item for the quarter ended 30th September, 2012 stands at Rs.7554 Lacs,  Rs.(613) Lacs, Rs. (-) 0.21 & Rs. (-) 0.14 respectively.
 
4. The figures of the previous period have been re-grouped/re-classified to conform to the current period's classification.
5. Extraordinary Items represent surplus accruing on account of settlement with Non Convertible Debenture holders.
6. Statement of Assets and Liabilities :
          (Rs. in Lacs)
  Particulars         As on As on
            30.09.2012 31.03.2012
            (Unaudited) (Audited)
A EQUITY AND LIABILITIES                  
1 Shareholders' Funds                  
  (a) Share Capital           20961     20961
  (b) Reserves and Surplus           13252   14349
    Shareholders' Funds         34213     35310
2 Non - Current Liabilities                  
  (a) Long term borrowings           10877     11389
  (b) Other Long term liabilities           225     243
  (c) Long term provisions           509     469
    Non- current liabilties         11611     12101
3 Current Liabilities                  
  (a) Trade Payables           5865     6359
  (b) Other current liablilities           4137     4320
  (c) Short term provisions           192     181
    Current liabilties         10194   10860
  TOTAL EQUITY AND LIABILITIES         56018     58271
B ASSETS                  
1 Non Current Assets                  
  (a) Fixed Assets           35347     37357
  (b) Non - current Investments           12181     12181
  (c) Long term loans and advances           162     155
    Non- current assets         47690     49693
2 Current Assets                  
  (a) Inventories           3624     3801
  (b) Trade receivables           3568     3313
  (c) Cash and cash equivalents           377     396
  (d) Short term loans and advances           617     900
  (e) Other current assets           142     168
    Current assets         8328     8578
  TOTAL ASSETS         56018     58271
                     
        For and on behalf of the Board
                     
Place: New Delhi             (Sushil Suri)
Date: 05.11.2012 Chairman & Managing Director